Get the Stockscreener App
1.65
3.12%
0.05
Longeveron Inc stock is traded at $1.65, with a volume of 293.49K.
It is up +3.12% in the last 24 hours and down -10.81% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$1.60
Open:
$1.59
24h Volume:
293.49K
Relative Volume:
0.62
Market Cap:
$24.48M
Revenue:
$709.00K
Net Income/Loss:
$-21.41M
P/E Ratio:
-1.7368
EPS:
-0.95
Net Cash Flow:
$-19.70M
1W Performance:
-11.29%
1M Performance:
-10.81%
6M Performance:
-32.65%
1Y Performance:
-89.81%
1-Day Range:
$1.59
$1.72
1-Week Range:
$1.59
$1.8899
52-Week Range:
$0.7707
$14.80
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.65 | 24.48M | 709.00K | -21.41M | -19.70M | -10.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron to Present at Biotech Showcase 2025 - The Manila Times
Longeveron CEO to Present at Biotech Showcase 2025: Spotlight on Regenerative Medicine Breakthroughs - StockTitan
Longeveron (NASDAQ:LGVN) Upgraded at Roth Capital - Defense World
Longeveron initiated with a Buy at Roth MKM - Yahoo Finance
Roth MKM Initiates Coverage of Longeveron (LGVN) with Buy Recommendation - MSN
Longeveron director Baluch Khoso sells $2,588 in stock By Investing.com - Investing.com Canada
Longeveron director Baluch Khoso sells $2,588 in stock - Investing.com
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 - Marketscreener.com
Longeveron FY2024 EPS Forecast Increased by HC Wainwright - Defense World
Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright reiterates Buy on Longeveron stock, raises target by 25% on trial progress - Investing.com India
Longeveron Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Longeveron stock opened 100% up on Wednesday: explore why - MSN
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Longeveron Inc - GuruFocus.com
The Escalator: Sanofi, Longeveron, Geron and more - MM+M Online
Earnings call: Longeveron Q3 2024 results show promise in regenerative medicine - Investing.com
Longeveron Inc. (NASDAQ:LGVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Longeveron reports Q3 EPS (34c), consensus (44c) - TipRanks
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
LGVNLongeveron Inc. Latest Stock News & Market Updates - StockTitan
A Look Ahead: Longeveron's Earnings Forecast - Benzinga
Longeveron names Devin Blass as new CTO - Investing.com
Longeveron names Devin Blass as new CTO By Investing.com - Investing.com UK
Longeveron Taps Devin Blass As CTO And SVP Of CMC - Contract Pharma
Longeveron Taps Devin Blass As CTO And SVP Of Chemistry, Manufacturing And Controls - Contract Pharma
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) - The Manila Times
Longeveron Strengthens Leadership: Key Executive Hire Ahead of Critical BLA Submission | LGVN Stock News - StockTitan
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 Result - Yahoo Finance
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - StockTitan
Peeling Back The Layers: Exploring Longeveron Through Analyst Insights - Benzinga
Longeveron presents Alzheimer's therapy data at CTAD24 - Investing.com
Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - The Manila Times
Longeveron presents Alzheimer's therapy data at CTAD24 By Investing.com - Investing.com UK
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) - StockTitan
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - ForexTV.com
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - GlobeNewswire Inc.
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Why has Longeveron stock tripled in two days? - MSN
Euro FX (E6N18) Quote - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Scholastic Corp (SCHL-Q) QuotePress Release - The Globe and Mail
LGVN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
LGVNRLongeveron Inc. Latest Stock News & Market Updates - StockTitan
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) - ForexTV.com
Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - The Manila Times
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected - GlobeNewswire
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):